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The functional assessment of multiple sclerosis (FAMS) is a disease-speciﬁc instrument that describes functional status of
individuals with multiple sclerosis. The instrument was originally developed in the US and has been adapted to diﬀerent
languages including Danish. This study is a validation of the Danish version of FAMS in a sample of individuals referred to a
four-week rehabilitation program at either of the two Multiple Sclerosis Rehabilitation centers in Denmark. FAMS data were
obtainedthroughself-completedquestionnairesfrom190individualswhoattendedtherehabilitationcentersafterreferralbytheir
general practitioner or specialist neurologist. The validation of the FAMS included assessment of data quality, scale assumptions,
acceptability, construct validity, and reliability. Responsiveness was assessed by comparing individual FAMS scores at admission
with the discharge score for groups of respondents who reported no change, improvement, or deterioration in their ability to
cope with their illness. The Danish version of FAMS appears to be an acceptable, valid, and reliable measure of current health and
functional status of individuals with multiple sclerosis.
1.Introduction
Multiple sclerosis is a chronic disease of the central nervous
system. The Danish national registry of multiple sclerosis
(MS) was started in 1956 [1]. The long history of this
registry enables the analysis of a wide range of epidemio-
logical studies, including analysis of the historical pattern of
MS development and health consequences. A recent study
estimated that 173 individuals per 100.000 population were
aﬀected by the disease, twice as many women as men [2].
The study found that the prevalence had increased three-
fold since 1950, probably more due to environmental factors
than genetic changes. Another study showed that the mean
survival time of patients with MS is reduced by 12-13 years
[3, 4], probably inﬂuenced by a suicide rate that is twice
as high as in the general population [5, 6] .T h es o c i a lc o s t
of Danish patients with MS is considerable and has been
estimated to exceed 232 mio. C in 2005 [7].
Assessment of patients’ health-related quality of life is
important in clinical evaluations, as clinical assessments
will not always reﬂect impact of illness and treatment on
the patient’s daily life [8]. MS can have signiﬁcant impact
on quality of life, for example, in the form of fatigue,
pain, and mobility problems [9]. Application of quality
of life instruments in clinical trials might oﬀer important
insight into patient’s perceived outcomes. The eﬀect of an
experimental intervention might be a lower reduction in
quality of life in comparison with the control intervention
which might suggest that the experimental intervention is
associatedwithmoredesirablehealthoutcomes.Asystematic
review of quality of life studies in MS identiﬁed 19 disease-
speciﬁc and 16 generic instruments that had been applied
in 81 diﬀerent studies [10]. However, none of the identiﬁed
instruments fully satisﬁed all assessment criteria, and most
oﬀer a compromise between ease of use and comprehen-
siveness. The choice of instrument is thus partly dependent2 Multiple Sclerosis International
on the objectives of measurement [10]. Instruments suitable
for clinical evaluations should fulﬁll a range of psychometric
properties including reliability, validity, and responsiveness
[11].
The functional assessment of multiple sclerosis (FAMS)
is one of the disease-speciﬁc quality of life instruments
available. It has been described as the best instrument for
assessing quality of life of patients with MS as it covers many
of the quality of life domains relevant to patients with MS
and has shown good convergent validity [10, 12]. The aim
of the current study was to validate the Danish version of
the FAMS instrument using a sample of individuals who
attendedalong-termprogramateitherofthetwospecialized
Danish centers for MS rehabilitation. The psychometric pro-
perties of the FAMS were tested by assessing validity, reli-
ability, and responsiveness to change.
2. Methods
2.1. Participants. The study sample consisted of individuals
referred by general practitioner or specialist neurologist to a
long-term rehabilitation program at the rehabilitation cen-
ters at Ry or Haslev and attended the centre between January
2007 and June 2008. The two centers are run by an inde-
pendent organization that provides specialized medical and
allied rehabilitation services to individuals with MS in line
with agreements with regional health authorities. Together,
the two centers have 78 beds and provide rehabilitation
services to more than 1000 patients annually. Participants
in this study were all admitted to a four-week standardized
rehabilitation program for which there is a waiting time of
5–12 months after referral.
After giving informed consent, participants completed
the FAMS at admission to the center. The data collection
was approved by the Danish Data Protection Agency (ID
no. 2009-41-3587). According to Danish regulations, studies
collecting questionnaire data only do not require review by
an ethics committee.
2.2. FAMS. The FAMS instrument was developed in Chi-
cago, USA to be included in clinical trials and clinical
processes.Thedevelopmentoftheinstrument[13]wasbased
on a pool of 88 questions generated from interviews with
patients and providers as well as review of the literature.
Principal component analysis and Rasch modeling were
applied to data from 377 patients with MS treated at two
specialized hospitals, resulting in a reduction of the initial
pool to 44 questions that were related to six domains: mobil-
ity, symptoms, emotional wellbeing (depression), general
contentment, thinking/fatigue, and family/social wellbeing.
In addition, 15 of the initial questions were retained due to
potential clinical or empirical value. The ﬁnal US version
comprises 59 statements where the respondents are asked to
indicate how true each statement has been for them during
the past 7 days, using the following ﬁve categories: not at all,
a little bit, and somewhat, quite a bit, and very much.
The scoring algorithm for FAMS assigns a value between
0a n d4t oe a c hr e s p o n s ec a t e g o r y .T h es c o r e so fn e g a t i v e l y
worded statements are reversed so, a high score consistently
reﬂects good functional status/quality of life. The scores are
added within each of the six subscales and then aggregated
into a total FAMS score. One subscale (thinking/fatigue) has
a range of 0–36, while the others have a range of 0–28. The
total FAMS score ranges between 0 and 176. In the case of
missing response items, a subscale score is derived based on
the valid responses and adjusted so that the score maintains
its full range.
The Danish version of FAMS had been previously trans-
lated and subsequently pilot tested among 90 MS patients
undergoing in-hospital rehabilitation [14].
2.3. Supplementary DataCollection. Every Danish citizen has
a unique personal identiﬁcation number that is used in
various national and local databases. This facilitated retrieval
of the respondents’ personal characteristics and enabled
questionnaire data to be linked to data from other sources.
In this study, clinical characteristics (type of MS, year of
MS diagnosis, and Expanded Disability Status Scale (EDSS)
score [15] at admission) were retrieved retrospectively from
medical records by clinical experts and were supplemented
by data from the local patient administrative systems.
2.4. Instrument Evaluation. This validation study was in-
spired by a validation study of the generic SF-36 instrument
[16] and validation studies of other MS-speciﬁc quality of
life instruments [12, 17, 18]. The FAMS instrument was
evaluated using the following criteria.
Data Quality. It indicates the extent to which a scale can be
used successfully in the target population and is determined
by examining the percentage of missing data. The scoring
procedure of FAMS includes a procedure for estimating
scores despite missing response items. It is thus possible
to derive scores for all scales, although the validity of the
scores is compromised with missing response items. A low
proportion of missing items is desirable, however.
Scaling Assumptions. They indicate whether it is legitimate
to generate a total score by summing item scores without
weightingorstandardization.Itissuggestedthatifindividual
items have item-subscale correlations exceeding 0.3, then
item weighting might not be required, and if items have
similar mean scores and variances, then standardization
might not be required [19].
Acceptability. It concerns the extent to which the range of
health measured by the scale matches the range of health in
the sample. Ideally, scores should span the whole scale range,
mean scores should be near the scale midpoint, ﬂoor/ceiling
eﬀects should be small (e.g., <15% of the sample), and
skewness statistics should lie in the range of −1t o+ 1[ 19].
Reliability. It concerns the extent to which the scale score is
free from random error. It can be determined by inspection
of Cronbach’s alpha coeﬃcient. When comparing patient
groups, it is recommended that reliability should exceed 0.7,Multiple Sclerosis International 3
and precision in analyzing individual patient scores requires
reliability exceeding 0.9 [16].
Construct Validity. It assesses the extent to which the in-
strument scores reﬂect expected relationships with other
measures. It was measured here primarily by known-group
comparisons, that is, patients with current active disease
(primary or secondary progressive) could be expected to
have worse scores than patients with remitting relapsing
MS [13]. Older patients could also be expected to have
lower scores. Another type of construct validity (convergent
validity) was also to be tested by comparing the FAMS
mobility subscale and the EDSS (ambulation) score.
Responsiveness. Was assessed by comparing the scores at
admission and discharge. Respondents were categorized
according to their reported change in satisfaction with the
way they handle their illness (this is question 51 in the
FAMS, but it is not used to derive subscale scores). As the
rehabilitation program aims at supporting participants to
cope with their illness, this question could be considered
as a proxy indicator for the outcome of the rehabilitation
intervention. Respondents were categorized according to
the diﬀerence between admission and discharge scores
as unchanged, better, or worse at discharge. Changes in
s c o r ew e r et e s t e dw i t hp a i r e dt-tests, where P values < 0.05
were considered statistically signiﬁcant. The eﬀect size was
calculated as the ratio of the change in the mean score and
the baseline score standard deviation. Estimates of 0.2–0.5
indicate a small eﬀect size, 0.5–0.8 a medium eﬀect size,
and over 0.8 a large eﬀect size [19]. Comparison of score
diﬀerences for respondents reporting better or worse state at
discharge in comparison with unchanged state are reported
as mean diﬀerences and 95% conﬁdence intervals.
3. Results
Table 1 presents the sample characteristics. Of the 190
individuals who completed the FAMS at admission, six did
not complete the FAMS at discharge. The 82 patients from
the Ry center scored signiﬁcantly lower on the FAMS total
score than those from the Haslev centre (105 versus 115
P = 0.02), otherwise there were no signiﬁcant diﬀerences
between patients at the two centers. There were no statistical
signiﬁcant diﬀerences in total FAMS score according to
gender (P = 0.84), 10-year age groups (P = 0.24), disease
duration (0.51), type of MS (P = 0.42), or ambulation status
(P = 0.32).
Table 2 presents results relating to data quality, scaling
assumption, acceptance, and reliability. The proportion of
missing items ranged from 5% to 11% percent in the six
subscales. However, more than a quarter of the respondents
did not provide valid response on at least one of the 44
questions. Two questions (Q41: “My family/close relatives
have accepted my illness” and Q42: “I am satisﬁed with
the way we talk about the illness in the family”) were left
unanswered by 43% and 45% of the respondents, respec-
tively, and two other questions (Q23: “I have accepted
Table 1: Characteristics of the study participants (n (%)).
Haslev
(n = 108)
Ry
(n = 82)
All
(n = 190)
Gender:
(i) men 42 (39%) 35 (43%) 77 (41%)
(ii) women 66 (61%) 47 (57%) 113 (59%)
Age group:
(i) under 40 years 12 (11%) 6 (7%) 18 (9%)
(ii) 40–49 years 31 (19%) 27 (33%) 58 (31%)
(iii) 50–59 years 30 (28%) 26 (32%) 56 (29%)
(iv) over 60 years 35 (32%) 23 (28%) 58 (31%)
Disease duration:
(i) 2 years or less 9 (8%) 13 (16%) 22 (12%)
(ii) 3–5 years 20 (18%) 9 (11%) 29 (15%)
(iii) 6–9 years 21 (19%) 21 (26%) 42 (22%)
(iv) 10–19 years 31 (29%) 29 (35%) 60 (32%)
(v) 20 years or more 25 (23%) 10 (12%) 35 (18%)
(vi) missing 2 (2%) 0 (0%) 2 (1%)
Type of MS:
(i) relapsing remitting 28 (26%) 28 (34%) 56 (29%)
(ii) secondary progressive 56 (52%) 42 (51%) 98 (52%)
(iii) primary progressive 22 (20%) 12 (15%) 34 (18%)
(iv) missing 2 (2%) 0 (0%) 2 (1%)
Ambulation status:
(i) walking independently
(EDSS < 5.5) 42 (39%) 30 (37%) 72 (38%)
(ii) walking with aid
(EDSS 6.0–6.5) 57 (53%) 38 (46%) 95 (50%)
(iii) wheelchair user
(EDSS > 7.0) 8 (7%) 14 (17%) 22 (12%)
(iv) missing 1 (1%) 0 (0%) 1 (1%)
EDSS= Expanded Disability Status Scale [15].
my illness” and Q24: “I am able to enjoy life”) were not
answered by 22% and 26%, respectively. Other questions
had nearly 100% completion (e.g., Q18: “I feel trapped by
my condition” and Q37: “I have trouble learning new tasks
or directions” each had <1% missing answers). It is worth
noting that nearly all the questions in the mobility subscale
had 10–12% missing responses.
Analysis of scaling assumptions showed that item-scale
correlations for the six subscales ranged from 0.36 to 0.83,
suggesting that a weighting of the items in the subscale is
unnecessary. The score ranges and variations are broadly
similar across subscales, such that standardization would
not be required. The only exception is perhaps the mobility
subscale, which had relatively low scores in comparison with
the other subscales.
The analysis of acceptability showed that the reported
scores covered a large section of the possible score ranges.
Only a few patients had the minimum or maximum subscale
scores, and no patients scored at the endpoints of the total
FAMS score. The analysis of skewness provided negative
values, reﬂecting relatively few low (poor health state) scores.4 Multiple Sclerosis International
Table 2: FAMS subscale scores and total score: data quality, scaling assumption, acceptability, and reliability (n = 190).
Psychometric property Mobility
(7 items)
Symptoms
(7 items)
Emotional
well-being
(7 items)
General
contentment
(7 items)
Thinking/
fatique
(9 items)
Family/social
well-being
(7 items)
FAMS total
(44 items)
Data quality
(i) Responses with missing
items (%) 11.0 5.8 7.4 7.4 6.3 5.3 26.8
Scale assumptions
(i) Subscore mean (range) 12.6 (1–27) 20.9 (6–28) 19.4 (1–28) 17.8 (0–28) 19.6 (0–35) 20.7 (5–28) 110.7 (34–167)
(ii) Item mean score 1.3–2.2 2.5–3.8 2.0–3.3 2.0–2.8 1.8–2.5 2.6–3.3 1.4–3.8
(iii) Item sd score 0.9–1.2 0.6–1.3 1.0–1.3 1.1–1.3 1.2–1.3 1.0–1.2 0.6–1.3
(iv) Item-scale correlation 0.53–0.77 0.36–0.79 0.65–0.84 0.63–0.83 0.66–0.81 0.68–0.80 0.10–0.77
Acceptability
(i) Possible score range 0–28 0–28 0–28 0–28 0–36 0–28 0–168
(ii) Observed score range 1–27 6–28 1–28 0–28 0–35 5–28 34–167
(iii) Mean score (SD) 12.6 (5.2) 20.9 (5.2) 19.4 (6.4) 17.8 (5.9) 19.6 (8.5) 20.7 (5.6) 110.7 (28.0)
(iv) Median (IQR) 12 (9–16) 22 (18–25) 21 (15–24) 18 (13–22) 20 (13–27) 22 (17–25) 114 (91–131)
(v) Floor/ceiling eﬀects (%) 0/0 0/7 0/6 1/2 1/0 0/8 0/0
(vi) Skewness 0.35 −0.73 −0.81 −0.35 −0.75 −0.75 −0.39
Reliability
(i) Cronbach’s alpha 0.79 0.79 0.90 0.62 0.91 0.85 0.94
Mobility was the only subscale with a positive skewness,
reﬂectingagreaternumberofrespondentswithhigherscores
(i.e., fewer problems with mobility).
In terms of reliability, all subscales except general con-
tentment reached the recommended level for group com-
parison (0.7), while not all the subscales reached the level
required for patient-level comparisons (0.9). Cronbach’s
alphaforthetotalFAMSscorewasof0.94,suggestingthatthe
scale has suﬃcient reliability for patient-level comparisons.
Table 3 shows the analysis of construct validity. As
could be expected, there were signiﬁcant score diﬀerences
between respondents with diﬀerent types of MS, and older
patients had lower (worse) mobility scores. Respondents at
the two centers diﬀered on the subscales for symptoms,
thinking/fatigue, and family/social well-being, which was
alsoreﬂectedinthetotalFAMSscore.Thisdiﬀerencebecame
insigniﬁcant after adjustment for patient characteristics such
as age, gender, disease duration, and EDSS score (OLS
regression, data not shown). There was a clear association
between mobility subscale score, and ambulation status
(EDSS score). The scores on the subscale thinking/fatigue
diﬀeredaccordingtodiseaseduration,buttheoverallpattern
was not clear as respondents with MS duration of 6–9 years
had relatively high scores.
Table 4 presents analysis of FAMS score changes over
time according to reported change in satisfaction with ability
tohandletheillness.Theeﬀectsizeforthepatientgroupwho
gave the same score on Q51 at discharge as at admission (n =
111) was positive but relatively low, ranging from 0.05 to
0.20. The changes in subscales scores were modest although
statistically signiﬁcant for symptoms, general contentment,
thinking/fatigue subscales, and the total FAMS score (all
slightly better at discharge).
Respondents who at discharge reported greater satisfac-
tion with ability to cope with the illness (Q51) also had
statistically higher scores on all subscales including the
total FAMS score. The eﬀect size ranged from 0.24 to
0.57, indicating low to medium responsiveness to change.
In comparison with the group that reported the same
score on Q51 at discharge, these “improved” patients had
statistically signiﬁcant score diﬀerences on all scores except
the symptoms and thinking/fatigue subscales.
Respondents who at discharge reported less satisfaction
with ability to cope with the illness (Q51) also had consis-
tently lower subscale scores and total FAMS score, although
only the family/social well-being subscale reached statistical
signiﬁcance. The eﬀect sizes were negative and ranged from
−0.03 to −0.25, indicating low responsiveness to change.
4. Discussion
The aim of this study was to evaluate the psychometric prop-
erties of the Danish version of the FAMS instrument based
on a sample of patients attending a four-week intervention
programattwospecializedcentersforMSrehabilitation.The
instrument showed adequate acceptability and reliability,
and there was evidence for construct validity and respon-
siveness to change. There were a high number of missing
responses on some items, but this was adjusted for in the
scoring algorithm.
The results from the current study are very similar to
the US validation study [13]. The scoring of the subscales
was broadly similar, although patients in the current study
had lower (worse) scores on mobility and higher (better)
scores on emotional well-being and general contentment.
The characteristics of the participants in the two studiesMultiple Sclerosis International 5
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were broadly similar, although there was a slightly higher
proportion of women in the US sample. The mean total
FAMS score was 108 (sd 28) in the current study and
111 (sd 27) in the US study. The reliability determined
by Cronbach’s alpha was also similar although the US
study reported higher alpha values for the mobility and
general contentment subscales. The ﬁndings relating to the
scaling assumptions were also similar, although the US study
reported higher item-subscale correlation for the mobility
items. The US study provided stronger support for construct
validity (ability to distinguish groups known to diﬀer from
one another), possibly due to a larger sample size (n = 377).
The current study showed good convergent validity for the
mobility subscale in a comparison against EDSS ambulation
status.
The current study was based on a group of consecutive
MS patients attending a four-week rehabilitation program
after referral from a general practitioner or neurological
specialist. Patients were referred to the rehabilitation centers
for a variety of indications, including physical rehabilitation
and treatment of neurological symptoms. As such, the study
samplereﬂectstypicalMSpatientsreferredforrehabilitation,
and the results are therefore likely to be generalizable to
other groups of MS patients attending routine rehabilitation
services.
The patients attending the two rehabilitation centers had
signiﬁcantly diﬀerent baseline scores on several subscales
and the total FAMS scale. However, this diﬀerence became
insigniﬁcant after adjustment for patient characteristics such
as age, gender, disease duration, and EDSS score.
It is envisaged that the FAMS instrument would be useful
inclinicalstudiesassessingtheimpactofvariousmedicaland
rehabilitation interventions in MS, in particular the eﬀect of
new medications. In cross-sectional analyses, the instrument
could also contribute to knowledge about quality of life in
diﬀerent groups of MS patients. With its seven subscales,
the FAMS instrument covers a broad range of aspects of
quality of life that are relevant to MS patients. This allows
the instrument to be used as a proﬁle measure (looking at
changes on speciﬁc aspects or domains of quality of life),
while the total FAMS score enables an overall assessment of
health state change.
A limitation of this validation study is that no other
health status instruments or assessments were administered
at the time of completion of the FAMS. This means that
testing of convergent and discriminant validity was not
possible, except for a limited analysis in which the FAMS
mobility subscale was compared with the EDSS ambulation
score. For lack of a better alternative, a proxy indicator for
outcome of the intervention program—the patients’ own
perception of how satisﬁed they were with their ability to
cope with the illness—was used. Given the limitations of
this approach (satisfaction with coping may not correlate
directly with, e.g., symptoms or emotional well-being), the
instrument appeared to be suﬃciently responsive to enable
identiﬁcation of changes in coping over time. Assessment
of test-retest properties of the FAMS instrument (i.e., in
patients whose functional health is not expected to change
in any major way over time) was not possible in this study.
We did not collect data on comorbidity in this study. This
would be useful in future studies as patient functional status
could be aﬀected by other illnesses or conditions besides MS.
5. Conclusion
Measurement of health outcomes is central for clinical
practice and health policy planning. In a disease like MS—
a chronic progressive disorder—outcomes that include the
patient’s own perspective are important. The Danish version
of FAMS appears to be an acceptable, valid and reliable
measure of the current health and functional status. Future
studies should assess the test-retest properties of FAMS
and how well FAMS correlates with other disease-speciﬁc
instruments such as the Multiple Sclerosis Impact Scale
(MSIS-29) and with generic health status measures such
as the SF-36/SF-12, EQ-5D, and 15D instruments. The
results from this study suggest that the FAMS is appropriate
for use in clinical trials to evaluate the eﬀect of medical
and rehabilitation interventions on patients’ physical and
psychosocial functioning.
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